Originally approved for treating type II diabetes, its benefits extend to broader metabolic management
Este pptido sinttico, Ipamorelin, es similar a la hormona del crecimiento natural, pero a diferencia de otros pptidos GHRH, no causa altos niveles de hiperglucemia (concentracin de glucosa en sangre)
Reasons for shortages: Very high demand for weight loss treatment Limited production Priority given to diabetes patients first Countries reporting shortages in 2025: United Kingdom Germany France Spain Italy Denmark Sweden To help manage this: Plan your prescription refills ahead of time Be flexible about the brand or dose if needed Be aware that temporary supply issues may occur
GLP-1 Lawsuits Targeting Vision Injuries Ozempic lawsuits claiming NAION and vision loss injuries have emerged following the 2024 and 2025 studies linking the drugs to a higher risk of developing NAION
Combining both remains well-tolerated when each is dosed conservatively and escalated gradually
Excess exposure to air means exposure to humidity (moisture) and airborne contaminants